Low Responders . | High Responders . | P . | Test . | ||
---|---|---|---|---|---|
Number | 54 | 20 | |||
Age (year) | 33.94 ± 1.922 | 30.59 ± 2.573 | 0.1584 | Mann-Whitney test | |
Sex | Female | 48.98% | 65.22% | 0.2169 | Fisher exact test |
Male | 51.02% | 34.78% | |||
Ethnicity | Caucasian | 78.72% | 95.00% | 0.1529 | Fisher exact test |
American Indian | 21.28% | 5.00% | |||
Albumin (g/dl) | 2.806 ± 0.1035 | 3.45 ± 0.16 | 0.0005 | Unpaired t test | |
Leucocytes (cells/ml) | 10109 ± 497.3 | 9920 ± 664.7 | 0.4157 | Mann-Whitney test | |
Lymphocytes (cells/ml) | 1368 ± 100.2 | 1845 ± 269.7 | 0.022 | Mann-Whitney test | |
Neutrophils (cells/ml) | 7566 ± 460.2 | 6866 ± 498.3 | 0.1804 | Mann-Whitney test | |
Monocytes (cells/mL) | 771.9 ± 66.76 | 839.0 ± 83.6 | 0.2769 | Mann-Whitney test | |
Neutrophil/Lymphocyte Ratio | 7.609 ± 0.9614 | 4.693 ± 0.50 | 0.0255 | Mann-Whitney test | |
Time of Disease Evolution (months) | 4.227 ± 0.4536 | 2.375 ± 0.4724 | 0.0118 | Mann-Whitney test | |
Radiology | Mild/Moderate | 24.00% | 42.11% | 0.0109 | Fisher exact test |
Severe | 76.00% | 57.89% | |||
AFB | 0/“+” | 18.75% | 55.00% | 0.0071 | Fisher exact test |
“++”/“+++” | 81.25% | 45.00% | |||
IFN-γ index | 29.2 ± 9.2 | 229.3 ± 70.4 | <0.0001 | Mann-Whitney test | |
Proliferation index | 7.0 ± 0.99 | 26.6 ± 2.9 | <0.0001 | Mann-Whitney test | |
Increase in the % of SLAMF1+ T cells | 2.2 ± 0.50 | 10.9 ± 1.4 | <0.0001 | Mann-Whitney test |
Low Responders . | High Responders . | P . | Test . | ||
---|---|---|---|---|---|
Number | 54 | 20 | |||
Age (year) | 33.94 ± 1.922 | 30.59 ± 2.573 | 0.1584 | Mann-Whitney test | |
Sex | Female | 48.98% | 65.22% | 0.2169 | Fisher exact test |
Male | 51.02% | 34.78% | |||
Ethnicity | Caucasian | 78.72% | 95.00% | 0.1529 | Fisher exact test |
American Indian | 21.28% | 5.00% | |||
Albumin (g/dl) | 2.806 ± 0.1035 | 3.45 ± 0.16 | 0.0005 | Unpaired t test | |
Leucocytes (cells/ml) | 10109 ± 497.3 | 9920 ± 664.7 | 0.4157 | Mann-Whitney test | |
Lymphocytes (cells/ml) | 1368 ± 100.2 | 1845 ± 269.7 | 0.022 | Mann-Whitney test | |
Neutrophils (cells/ml) | 7566 ± 460.2 | 6866 ± 498.3 | 0.1804 | Mann-Whitney test | |
Monocytes (cells/mL) | 771.9 ± 66.76 | 839.0 ± 83.6 | 0.2769 | Mann-Whitney test | |
Neutrophil/Lymphocyte Ratio | 7.609 ± 0.9614 | 4.693 ± 0.50 | 0.0255 | Mann-Whitney test | |
Time of Disease Evolution (months) | 4.227 ± 0.4536 | 2.375 ± 0.4724 | 0.0118 | Mann-Whitney test | |
Radiology | Mild/Moderate | 24.00% | 42.11% | 0.0109 | Fisher exact test |
Severe | 76.00% | 57.89% | |||
AFB | 0/“+” | 18.75% | 55.00% | 0.0071 | Fisher exact test |
“++”/“+++” | 81.25% | 45.00% | |||
IFN-γ index | 29.2 ± 9.2 | 229.3 ± 70.4 | <0.0001 | Mann-Whitney test | |
Proliferation index | 7.0 ± 0.99 | 26.6 ± 2.9 | <0.0001 | Mann-Whitney test | |
Increase in the % of SLAMF1+ T cells | 2.2 ± 0.50 | 10.9 ± 1.4 | <0.0001 | Mann-Whitney test |
Immunological classification of TB patients as High and Low Responders (HR and LR) was performed according to the IFN-γ index; proliferation index and increase in the percentage of SLAMF1+ T cells in response to Mtb-Ag stimulation. Clinical symptoms analyzed in TB patients previous to hospital admission to establish the time (months) of disease evolution were: weight loss, night sweats, symptoms of malaise or weakness, persistent fever, presence of cough, history of shortness of breath, and hemoptysis. Radiological lesions: “mild” corresponds to patients with a single lobe involved and without visible cavities; “moderate” relates to patients presenting unilateral involvement of two or more lobes with cavities, if present, reaching a total diameter no greater than 4 cm; “severe” corresponds to bilateral disease with massive affectation and multiple cavities. Acid-Fast Bacilli (AFB) in sputum smear represent: AFB-, 0 bacilli count; AFB +, 1–9 bacilli/100 fields; AFB + +, 1–9 bacilli/10 fields; AFB + + + , 1–9 bacilli/field. Continuous data are expressed as mean ± SEM, and categorical data are expressed as number (percentages).
Low Responders . | High Responders . | P . | Test . | ||
---|---|---|---|---|---|
Number | 54 | 20 | |||
Age (year) | 33.94 ± 1.922 | 30.59 ± 2.573 | 0.1584 | Mann-Whitney test | |
Sex | Female | 48.98% | 65.22% | 0.2169 | Fisher exact test |
Male | 51.02% | 34.78% | |||
Ethnicity | Caucasian | 78.72% | 95.00% | 0.1529 | Fisher exact test |
American Indian | 21.28% | 5.00% | |||
Albumin (g/dl) | 2.806 ± 0.1035 | 3.45 ± 0.16 | 0.0005 | Unpaired t test | |
Leucocytes (cells/ml) | 10109 ± 497.3 | 9920 ± 664.7 | 0.4157 | Mann-Whitney test | |
Lymphocytes (cells/ml) | 1368 ± 100.2 | 1845 ± 269.7 | 0.022 | Mann-Whitney test | |
Neutrophils (cells/ml) | 7566 ± 460.2 | 6866 ± 498.3 | 0.1804 | Mann-Whitney test | |
Monocytes (cells/mL) | 771.9 ± 66.76 | 839.0 ± 83.6 | 0.2769 | Mann-Whitney test | |
Neutrophil/Lymphocyte Ratio | 7.609 ± 0.9614 | 4.693 ± 0.50 | 0.0255 | Mann-Whitney test | |
Time of Disease Evolution (months) | 4.227 ± 0.4536 | 2.375 ± 0.4724 | 0.0118 | Mann-Whitney test | |
Radiology | Mild/Moderate | 24.00% | 42.11% | 0.0109 | Fisher exact test |
Severe | 76.00% | 57.89% | |||
AFB | 0/“+” | 18.75% | 55.00% | 0.0071 | Fisher exact test |
“++”/“+++” | 81.25% | 45.00% | |||
IFN-γ index | 29.2 ± 9.2 | 229.3 ± 70.4 | <0.0001 | Mann-Whitney test | |
Proliferation index | 7.0 ± 0.99 | 26.6 ± 2.9 | <0.0001 | Mann-Whitney test | |
Increase in the % of SLAMF1+ T cells | 2.2 ± 0.50 | 10.9 ± 1.4 | <0.0001 | Mann-Whitney test |
Low Responders . | High Responders . | P . | Test . | ||
---|---|---|---|---|---|
Number | 54 | 20 | |||
Age (year) | 33.94 ± 1.922 | 30.59 ± 2.573 | 0.1584 | Mann-Whitney test | |
Sex | Female | 48.98% | 65.22% | 0.2169 | Fisher exact test |
Male | 51.02% | 34.78% | |||
Ethnicity | Caucasian | 78.72% | 95.00% | 0.1529 | Fisher exact test |
American Indian | 21.28% | 5.00% | |||
Albumin (g/dl) | 2.806 ± 0.1035 | 3.45 ± 0.16 | 0.0005 | Unpaired t test | |
Leucocytes (cells/ml) | 10109 ± 497.3 | 9920 ± 664.7 | 0.4157 | Mann-Whitney test | |
Lymphocytes (cells/ml) | 1368 ± 100.2 | 1845 ± 269.7 | 0.022 | Mann-Whitney test | |
Neutrophils (cells/ml) | 7566 ± 460.2 | 6866 ± 498.3 | 0.1804 | Mann-Whitney test | |
Monocytes (cells/mL) | 771.9 ± 66.76 | 839.0 ± 83.6 | 0.2769 | Mann-Whitney test | |
Neutrophil/Lymphocyte Ratio | 7.609 ± 0.9614 | 4.693 ± 0.50 | 0.0255 | Mann-Whitney test | |
Time of Disease Evolution (months) | 4.227 ± 0.4536 | 2.375 ± 0.4724 | 0.0118 | Mann-Whitney test | |
Radiology | Mild/Moderate | 24.00% | 42.11% | 0.0109 | Fisher exact test |
Severe | 76.00% | 57.89% | |||
AFB | 0/“+” | 18.75% | 55.00% | 0.0071 | Fisher exact test |
“++”/“+++” | 81.25% | 45.00% | |||
IFN-γ index | 29.2 ± 9.2 | 229.3 ± 70.4 | <0.0001 | Mann-Whitney test | |
Proliferation index | 7.0 ± 0.99 | 26.6 ± 2.9 | <0.0001 | Mann-Whitney test | |
Increase in the % of SLAMF1+ T cells | 2.2 ± 0.50 | 10.9 ± 1.4 | <0.0001 | Mann-Whitney test |
Immunological classification of TB patients as High and Low Responders (HR and LR) was performed according to the IFN-γ index; proliferation index and increase in the percentage of SLAMF1+ T cells in response to Mtb-Ag stimulation. Clinical symptoms analyzed in TB patients previous to hospital admission to establish the time (months) of disease evolution were: weight loss, night sweats, symptoms of malaise or weakness, persistent fever, presence of cough, history of shortness of breath, and hemoptysis. Radiological lesions: “mild” corresponds to patients with a single lobe involved and without visible cavities; “moderate” relates to patients presenting unilateral involvement of two or more lobes with cavities, if present, reaching a total diameter no greater than 4 cm; “severe” corresponds to bilateral disease with massive affectation and multiple cavities. Acid-Fast Bacilli (AFB) in sputum smear represent: AFB-, 0 bacilli count; AFB +, 1–9 bacilli/100 fields; AFB + +, 1–9 bacilli/10 fields; AFB + + + , 1–9 bacilli/field. Continuous data are expressed as mean ± SEM, and categorical data are expressed as number (percentages).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.